ATP依赖的染色质重塑复合物与肺癌研究进展(4)
[3] Racki L R，Narlikar G J.ATP-dependent chromatin remodeling enzymes：two heads are not better，just different[J].Current Opinion in Genetics & Development，2008，18(2)：137-144.
[4] Wang G G，Allis C D，Chi P.Chromatin remodeling and cancer，PartⅠ：Covalent histone modifications[J].Trends in Molecular Medicine，2007，13(9)：363-372.
[5] Gangaraju V K，Bartholomew B.Mechanisms of ATP Dependent Chromatin Remodeling[J].Mutation Research/fundamental & Molecular Mechanisms of Mutagenesis，2007，618(1-2)：3.
, http://www.100md.com
[6] Liu G，Gramling S，Munoz D，et al.Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk[J].Oncogene，2011，30(29)：3295-3304.
[7] Wu J N，Roberts C W M.ARID1A Mutations in Cancer： Another Epigenetic Tumor Suppressor[J].Cancer Discovery，2013，3(1)：35-43.
[8] Reisman D N，Sciarrotta J，Wang W，et al.Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers：correlation with poor prognosis[J].Cancer Research，2003，63(3)：560-566.
, 百拇医药
[9] Yoshimoto T，Matsubara D，Nakano T，et al.Frequent loss of the expression of multiple subunits of the SWI/SNF complex in large cell carcinoma and pleomorphic carcinoma of the lung[J].Pathology International，2015，65(11)：595.
[10] Rodriguez-Nieto S，Canada A，Pros E，et al.Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors[J].Hum Mutat，2011，32(2)：E1999-E2017.
[11] Zhou Z，Su Y，Xianen F.Restoration of BRG1 inhibits proliferation and metastasis of lung cancer by regulating tumor suppressor miR-148b[J].Oncotargets & Therapy，2015，8：3603-3612.
, http://www.100md.com
[12] Tagal V，Wei S，Zhang W，et al.SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor
VX-680 in non-small cell lung cancers[J].Nature Communications，2017，8：14098.
[13] Fillmore C M，Xu C，Desai P T，et al.EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoⅡ inhibitors[J].Nature，2015，520(7546)：239.
[14] Bell E H，Chakraborty A R，Mo X，et al.SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research，2015，22(10)：2396.
[15] Herpel E，Rieker R J，Dienemann H，et al.SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer：immunohistochemical survey of 316 consecutive specimens[J].Annals of Diagnostic Pathology，2017，26：47-51., 百拇医药(黄礼治 荣福)
[4] Wang G G，Allis C D，Chi P.Chromatin remodeling and cancer，PartⅠ：Covalent histone modifications[J].Trends in Molecular Medicine，2007，13(9)：363-372.
[5] Gangaraju V K，Bartholomew B.Mechanisms of ATP Dependent Chromatin Remodeling[J].Mutation Research/fundamental & Molecular Mechanisms of Mutagenesis，2007，618(1-2)：3.
, http://www.100md.com
[6] Liu G，Gramling S，Munoz D，et al.Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk[J].Oncogene，2011，30(29)：3295-3304.
[7] Wu J N，Roberts C W M.ARID1A Mutations in Cancer： Another Epigenetic Tumor Suppressor[J].Cancer Discovery，2013，3(1)：35-43.
[8] Reisman D N，Sciarrotta J，Wang W，et al.Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers：correlation with poor prognosis[J].Cancer Research，2003，63(3)：560-566.
, 百拇医药
[9] Yoshimoto T，Matsubara D，Nakano T，et al.Frequent loss of the expression of multiple subunits of the SWI/SNF complex in large cell carcinoma and pleomorphic carcinoma of the lung[J].Pathology International，2015，65(11)：595.
[10] Rodriguez-Nieto S，Canada A，Pros E，et al.Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors[J].Hum Mutat，2011，32(2)：E1999-E2017.
[11] Zhou Z，Su Y，Xianen F.Restoration of BRG1 inhibits proliferation and metastasis of lung cancer by regulating tumor suppressor miR-148b[J].Oncotargets & Therapy，2015，8：3603-3612.
, http://www.100md.com
[12] Tagal V，Wei S，Zhang W，et al.SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor
VX-680 in non-small cell lung cancers[J].Nature Communications，2017，8：14098.
[13] Fillmore C M，Xu C，Desai P T，et al.EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoⅡ inhibitors[J].Nature，2015，520(7546)：239.
[14] Bell E H，Chakraborty A R，Mo X，et al.SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research，2015，22(10)：2396.
[15] Herpel E，Rieker R J，Dienemann H，et al.SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer：immunohistochemical survey of 316 consecutive specimens[J].Annals of Diagnostic Pathology，2017，26：47-51., 百拇医药(黄礼治 荣福)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺肿瘤 > 肺癌